U.S. Markets close in 4 hrs 53 mins

Wired News – Capricor’s New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular Dystrophy

Stock Monitor: Kala Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on Capricor Therapeutics, Inc. (NASDAQ: CAPR) ("Capricor"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CAPR as the Company's latest news hit the wire. On April 19, 2018, the Company announced that its pre-clinical study has established that repeated dosing of its lead candidate, CAP-1002, yields an increase in exercise performance in a disease model of Duchenne Muscular Dystrophy (DMD), the mdx mouse. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Kala Pharmaceuticals, Inc. (NASDAQ: KALA), which also belongs to the Healthcare sector as the Company Capricor Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=KALA

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Capricor Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CAPR

Repeat Dosing of CAP-1002 Resulted in Improvements in Absolute Force in Soleus and Diaphragm of a Mouse Model of DMD

Researchers reported that while CAP-1002 is recognized by the immune system, its low immunogenic profile and immunomodulatory capabilities allowed it to be administered multiple times without significant safety issues. It was also reported that repeat dosing was shown to sustain the effect of the therapeutic. The research found improvements in absolute force in soleus (leg) and in the diaphragm of a mouse model of DMD, the mdx mouse. Additionally, decreased fibrosis in skeletal and cardiac muscles after three administrations of CAP-1002 was observed.

Findings were Foundation for Design of HOPE-2 Clinical Trial

These findings were the foundation for the design of the HOPE-2 clinical trial that Capricor will initiate shortly. The HOPE-2 clinical trial will test the safety and efficacy of repeat doses of CAP-1002 in boys and young men with DMD. Up to 84 boys and young men with DMD will be enrolled in the Phase-2, randomized, double-blind, placebo-controlled trial. HOPE-2 will test repeat doses of CAP-1002 in participants with advanced stages of DMD.

CAP-1002 has Potential to Work Synergistically with Gene Therapies for DMD

Linda Marbán, Ph.D., President and Chief Executive Officer (CEO) at Capricor, stated that the Company is eager to get the HOPE-2 trial underway as it may potentially be a registration trial, and also because the potential for improvements in muscle function in both pre-clinical studies and in the Company's earlier HOPE-Duchenne clinical trial was observed. Marbán added that CAP-1002 also has the potential to work synergistically with gene and other therapies for DMD.

Capricor Received FDA's Regenerative Medicine Advanced Therapy Designation for DMD Therapy

On February 05, 2018, the US Food and Drug Administration (FDA) granted the candidate CAP-1002 with a Regenerative Medicine Advanced Therapy (RMAT) designation for DMD Therapy. To receive the RMAT designation, Capricor submitted data from an earlier trial, the HOPE-Duchenne Trial, which reported significant and sustained improvements in skeletal muscle function and cardiac structure in boys and young men in advanced stages of DMD, following a single dose of intracoronary CAP-1002.

The FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation to CAP-1002 in August 2015 and July 2017, respectively.

About Duchenne Muscular Dystrophy (DMD)

DMD is a genetic disorder characterized by progressive muscle degeneration and weakness. It is one of nine types of muscular dystrophy. DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between the ages of 3 and 5. The disease primarily affects boys, but in rare cases can also affect girls.

About CAP-1002

CAP-1002 consists of allogeneic cardiosphere-derived cells (CDCs), a unique population of cells that contains cardiac progenitor cells. CAP-1002 has been shown to exert potent immunomodulatory activity and stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials.

About Capricor Therapeutics, Inc.

Founded in 2005 and headquartered in Beverly Hills, California, Capricor is a clinical-stage biotechnology organization focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.

Stock Performance Snapshot

April 20, 2018 - At Friday's closing bell, Capricor Therapeutics' stock dropped 6.16%, ending the trading session at $1.37.

Volume traded for the day: 317.68 thousand shares.

After last Friday's close, Capricor Therapeutics' market cap was at $39.40 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors